<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627521</url>
  </required_header>
  <id_info>
    <org_study_id>REB#13-287</org_study_id>
    <nct_id>NCT02627521</nct_id>
  </id_info>
  <brief_title>Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor</brief_title>
  <acronym>CABG-TIME</acronym>
  <official_title>Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of Ticagrelor have demonstrated superiority to Clopidogrel in patients
      presenting with acute coronary syndrome (ACS) and remains a first line therapy as an adjunct
      to aspirin for patients admitted with ACS. The patient population treated with Ticagrelor at
      an early time point includes non ST elevation myocardial (NSTEMI) patients and those
      undergoing primary angioplasty for ST elevation myocardial infarction (STEMI). It is
      estimated that 10-15% of patients presenting with ACS have advanced coronary artery disease
      requiring Coronary Artery Bypass Surgery (CABG). The treatment guidelines recommend a delay
      of 5-7 days for CABG surgery in these patients for normalization of Ticagrelor induced
      platelet inhibition to reduce the risk of peri-operative bleeding. This delay may expose
      these high risk patients to adverse cardiac events while waiting for Ticagrelor effect to
      wean off. Furthermore, this empirical application of 5-7 day delay in all patients may be
      unnecessary due to the significant inter individual variability in response to Ticagrelor.
      There is limited data to determine the optimum timing of CABG surgery in ACS patients treated
      with Ticagrelor. The present study will determine the optimum timing of CABG in ACS patients
      treated with a loading and/or maintenance dose of Ticagrelor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 30 day</time_frame>
    <description>The primary efficacy endpoint of the study is the total length of hospital stay (LOS) for CABG surgery between the two groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PRU Guided CABG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value &gt;235 or a PRU value between &gt;170 and &lt;235 for two consecutive days as documented by VerifyNow assay.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG per standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timing of CABG per standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PRU guided CABG</intervention_name>
    <description>Coronary Artery Bypass Surgery</description>
    <arm_group_label>PRU Guided CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG per standard of care</intervention_name>
    <description>Coronary Artery Bypass Surgery</description>
    <arm_group_label>CABG per standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VerifyNow assay</intervention_name>
    <description>Platelet reactivity Units by VerifyNow assay</description>
    <arm_group_label>PRU Guided CABG</arm_group_label>
    <arm_group_label>CABG per standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor administration prior to randomization</description>
    <arm_group_label>PRU Guided CABG</arm_group_label>
    <arm_group_label>CABG per standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accepted for CABG surgery

          -  Treatment with Ticagrelor within 48 hours

        Exclusion Criteria:

          -  Anticoagulation therapy

          -  Prior CABG.

          -  Active bleeding or at high risk of bleeding

          -  Severe liver or renal disease.

          -  Hypersensitivity to ticagrelor

          -  History of intracranial hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asim Cheema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asim Cheema, MD</last_name>
    <phone>4168645739</phone>
    <email>cheemaa@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ishba Syed, MBBS</last_name>
    <phone>4168646060</phone>
    <phone_ext>77191</phone_ext>
    <email>syedi@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Michael's hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asim Cheema, MD</last_name>
      <phone>416-864-5739</phone>
      <email>cheemaA@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

